Literature DB >> 25452393

Factorial clinical trials: a new approach to phase II neuro-oncology studies.

Fabio M Iwamoto1, Andrew B Lassman1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25452393      PMCID： PMC4288526          DOI： 10.1093/neuonc/nou314

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  11 in total

1.  Factorial design considerations.

Authors:  Stephanie Green; Ping-Yu Liu; Janet O'Sullivan
Journal:  J Clin Oncol       Date:  2002-08-15       Impact factor: 44.544

2.  Testing for the presence of positive-outcome bias in peer review: a randomized controlled trial.

Authors:  Gwendolyn B Emerson; Winston J Warme; Fredric M Wolf; James D Heckman; Richard A Brand; Seth S Leopold
Journal:  Arch Intern Med       Date:  2010-11-22

3.  CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010.

Authors:  Quinn T Ostrom; Haley Gittleman; Paul Farah; Annie Ondracek; Yanwen Chen; Yingli Wolinsky; Nancy E Stroup; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2013-11       Impact factor: 12.300

4.  NIH clinical trials and publication bias.

Authors:  K Dickersin; Y I Min
Journal:  Online J Curr Clin Trials       Date:  1993-04-28

5.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

Authors:  Olivier L Chinot; Wolfgang Wick; Warren Mason; Roger Henriksson; Frank Saran; Ryo Nishikawa; Antoine F Carpentier; Khe Hoang-Xuan; Petr Kavan; Dana Cernea; Alba A Brandes; Magalie Hilton; Lauren Abrey; Timothy Cloughesy
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

6.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

7.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

8.  Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.

Authors:  Marta Penas-Prado; Kenneth R Hess; Michael J Fisch; Lore W Lagrone; Morris D Groves; Victor A Levin; John F De Groot; Vinay K Puduvalli; Howard Colman; Gena Volas-Redd; Pierre Giglio; Charles A Conrad; Michael E Salacz; Justin D Floyd; Monica E Loghin; Sigmund H Hsu; Javier Gonzalez; Eric L Chang; Shiao Y Woo; Anita Mahajan; Kenneth D Aldape; W K Alfred Yung; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2014-09-19       Impact factor: 12.300

9.  Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis.

Authors:  Joseph S Ross; Tony Tse; Deborah A Zarin; Hui Xu; Lei Zhou; Harlan M Krumholz
Journal:  BMJ       Date:  2012-01-03

10.  A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; Javier Gonzalez; Kathy Hunter; Kenneth Hess; Pierre Giglio; Eric Chang; Vinay Puduvalli; Morris D Groves; Howard Colman; Charles Conrad; Victor Levin; Shaio Woo; Anita Mahajan; John de Groot; W K Alfred Yung
Journal:  Neuro Oncol       Date:  2010-08-20       Impact factor: 12.300
View more
  1 in total

Review 1.  Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank.

Authors:  Pavlina Chuntova; Frances Chow; Payal B Watchmaker; Mildred Galvez; Amy B Heimberger; Evan W Newell; Aaron Diaz; Ronald A DePinho; Ming O Li; E John Wherry; Duane Mitchell; Masaki Terabe; Derek A Wainwright; Jay A Berzofsky; Christel Herold-Mende; James R Heath; Michael Lim; Kim A Margolin; E Antonio Chiocca; Noriyuki Kasahara; Benjamin M Ellingson; Christine E Brown; Yvonne Chen; Peter E Fecci; David A Reardon; Gavin P Dunn; Linda M Liau; Joseph F Costello; Wolfgang Wick; Timothy Cloughesy; William C Timmer; Patrick Y Wen; Robert M Prins; Michael Platten; Hideho Okada
Journal:  Neuro Oncol       Date:  2021-03-25       Impact factor: 12.300
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.